ProCE Banner Activity

CME

Hodgkin Lymphoma: Expert Insights on Optimizing Frontline Treatment Options for Pediatric and AYA Patient Populations

Video

Watch this on-demand webcast from a live ASPHO satellite symposium to learn from expert pediatric hematologists about optimizing frontline treatment options for pediatric and AYA patient populations with Hodgkin lymphoma, including new clinical data, managing adverse events with novel agents, and available clinical trials enrolling in the frontline setting.

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: June 13, 2023

Expiration: June 12, 2024

No longer available for credit.

Share

Faculty

Kara M. Kelly

Kara M. Kelly, MD

Chair
Professor of Oncology
Pediatric Hematology and Oncology 
Roswell Park Comprehensive Cancer Center 
Buffalo, New York 

Lisa Giulino Roth

Lisa Giulino Roth, MD

Director, Pediatric Oncology
Associate Professor of Pediatrics, Pediatric Hematology/Oncology
Weill Cornell Medicine
New York, New York

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from Seagen.

Seagen

Target Audience

This activity is intended for pediatric hematologists and other allied healthcare professionals who treat or manage children, adolescents, and young adults with Hodgkin lymphoma.

Program Learning Goal

The goal of this program is to improve the knowledge and competence of learners in an effort to optimize treatment for pediatric and AYA patients with Hodgkin lymphoma.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Apply new treatment options to improve frontline therapy for pediatric and AYA patients with HL considering patient-related factors and risk stratification

  • Devise proactive measures for identifying, monitoring, and addressing treatment-related adverse events associated with modern frontline therapy approaches

  • Recall the design of ongoing clinical trials evaluating emerging treatment options in the frontline setting for pediatric and AYA patients with HL and provide information on availability and participation

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

Kara M. Kelly, MD

Chair
Professor of Oncology
Pediatric Hematology and Oncology 
Roswell Park Comprehensive Cancer Center 
Buffalo, New York 

Kara Kelly, MD: consultant/advisor/speaker: Seagen; researcher (paid to institution): BMS and Merck. 

Lisa Giulino Roth, MD

Director, Pediatric Oncology
Associate Professor of Pediatrics, Pediatric Hematology/Oncology
Weill Cornell Medicine
New York, New York

Lisa Giulino Roth, MD: consultant/advisor/speaker: Merck; research funds (paid to institution): Roche.

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1 hours. To successfully complete this activity and receive credit, learners must follow these steps during the period from June 13, 2023, through June 12, 2024:

  1. Login or Sign Up for an account by clicking at the top of this page.
  2. Read the target audience, learning objectives, and faculty disclosures.
  3. View and study the content in its entirety.
  4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.

Format

This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement

In support of improving patient cate, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

CCO designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.